Saint prex

SAINT-PREX, Switzerland, August 31, 2011 - - Rapid and sustained testosterone suppression and improved PSA control may delay time to second-line therapy New data, published in the September issue of TheJournal of Urology, showed that long-term use of FIRMAGON (degarelix) a gonadotropin-releasing hormone therapy (GnRH) approved for the treatment of advanced prostate cancer in both the EU and US, continued to be effective and well tolerated beyond three years.[1] The new study (CS21A) extends the conclusions of the pivotal Phase III study (CS21) in which the risk of prostate-specific antigen (PSA) failure or death was significantly lower in patients on FIRMAGON compared to leuprolide (an LHRH agonist) up to one year.[1] The extension study has now shown that for patients who remained on FIRMAGON, PSA suppression and the effects on PSA progression free survival (PFS) remained consistent over the long term (42 months).[1] In addition, the study looked at patients who crossed over from leuprolide to FIRMAGONafter one year.

SAINT-PREX, Switzerland, May 10, 2010 - Ferring Pharmaceuticals today announced an agreement that will expand its Women's Health product portfolio with the acquisition of the global rights to Xanodyne Pharmaceutical's LYSTEDA(TM) (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB).

SAINT-PREX, Switzerland, December 21 - Results from a phase III pivotal study sub-analyses reported in European Urology show that prostate cancer patients who received Firmagon(R) (degarelix) in the study have a statistically significant greater probability of PSA (prostate-specific-antigen) recurrence-free survival compared with those taking leuprolide (P=0.05).

SAINT PREX, Switzerland - Frederik Paulsen, Chairman of Ferring Pharmaceuticals, a pharmaceutical company with presence in all major European markets and in the US, announced a US$3 million donation to the Royal Textile Academy of Bhutan.